Drug Update - July 2015
Posted: Jul 10 2015

FDA Drug Approvals

Each month the FDA approves new medications, and below is a highlight of the most relevant new approvals and/or drugs which have the potential to impact your prescription plan. While the medications below have been evaluated and approved by the FDA, they may not enter the marketplace for several weeks or months. Therefore, pricing information for these medications is typically unavailable at the time of approval.

New Generic Approvals
Drug NameUses/TreatmentPlan Impact & CCC Management Strategy
Ezetimibe
(generic for Zetia)
Treatment of various dyslipidemias (e.g. hyperlipidemia)Drug Information: Zetia is a cholesterol absorption inhibitor and is listed on MedTrak’s Top 100 Drugs by Cost report.  Ezetimibe is anticipated to be available from a single manufacturer upon market entry.
Formulary Management: All generic products will price at the Plan’s lowest copayment tier (applies to copayment Plans only). 
Control Trak: Subject to Max Dollar and Max Dose edits.
Desvenlafaxine succinate
(generic for Pristiq)
Treatment of major depressive disorder (MDD)Drug Information:  Pristiq is a SNRI antidepressant and is present on MedTrak’s Top 100 Drugs by Cost report.  Desvenlafaxine is anticipated to be available from multiple manufacturers upon market entry. 
Formulary Management: All generic products will price at the Plan’s lowest copayment tier (applies to copayment Plans only). 
Clinical Concierge: Pristiq is currently managed as a Step Two agent as part of the SNRI Step Therapy program.  Re-evaluation of desvenlafaxine’s placement as a Step Two agent will occur once pricing information is available.
Control Trak: Subject to Max Dollar and Max Dose edits.
Zolpidem tartrate (generic for Intermezzo)Treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep Drug Information: Intermezzo contains the same active ingredient found in Ambien and is formulated as a sublingual (under the tongue) tablet.
Formulary Management: All generic products will price at the Plan’s lowest copayment tier (Applies to copayment Plans only). 
Clinical Concierge: Intermezzo is currently managed as a Step Two agent as part of the Sedative and Hypnotic Step Therapy program. Re-evaluation of zolpidem’s placement as a Step Two agent will occur once pricing information is available.
Control Trak: Subject to Max Dollar and Max Dose edits.

The Clinical Care Center (CCC) is MedTrak’s comprehensive clinical solution to control costs and increase adherence for our Clients and Members. The Clinical Care Center is made up of 7 Steps to Improved Outcomes: Generics Plus, Formulary Management, Member & Client Education, RightChoice, Control Trak, Best-In-Class (BIC) SpecialtyRx, and Clinical Concierge.